Full Text of HB5233 97th General Assembly
HB5233 97TH GENERAL ASSEMBLY |
| | 97TH GENERAL ASSEMBLY
State of Illinois
2011 and 2012 HB5233 Introduced 2/8/2012, by Rep. Jerry F. Costello, II SYNOPSIS AS INTRODUCED: |
| 410 ILCS 620/2.4 | from Ch. 56 1/2, par. 502.4 | 410 ILCS 620/3.22 | from Ch. 56 1/2, par. 503.22 | 410 ILCS 620/5 | from Ch. 56 1/2, par. 505 | 410 ILCS 620/6 | from Ch. 56 1/2, par. 506 | 720 ILCS 570/204 | from Ch. 56 1/2, par. 1204 |
|
Amends the Illinois Food, Drug and Cosmetic Act. Sets forth a definition for "synthetic drug product". Provides that whoever distributes, or possesses with intent to distribute, a synthetic drug product or a drug that is misbranded under the Act is guilty of a Class 2 felony and may be fined an amount not to exceed $100,000 and that a person convicted of a second or subsequent violation is guilty of a Class 1 felony, the fine for which shall not exceed $250,000. Provides that whoever falsely advertises a synthetic drug product or a drug that is misbranded is guilty of a Class 3 felony and may be fined an amount not to exceed $100,000. Makes changes to provisions concerning the classifications of certain violations and authorized agents of the Director of Public Health. Amends the Illinois Controlled Substances Act to include pentedrone in the list of controlled substances that are
included in Schedule I.
|
| |
| | CORRECTIONAL BUDGET AND IMPACT NOTE ACT MAY APPLY | | FISCAL NOTE ACT MAY APPLY |
| | A BILL FOR |
|
| | | HB5233 | | LRB097 20167 RPM 65645 b |
|
| 1 | | AN ACT concerning public health.
| 2 | | Be it enacted by the People of the State of Illinois,
| 3 | | represented in the General Assembly:
| 4 | | Section 5. The Illinois Food, Drug and Cosmetic Act is | 5 | | amended by changing Sections 2.4, 3.22, 5, and 6 as follows:
| 6 | | (410 ILCS 620/2.4) (from Ch. 56 1/2, par. 502.4)
| 7 | | Sec. 2.4.
(a) "Drug" means (1) articles recognized in the | 8 | | official United
States Pharmacopoeia - National Formulary, | 9 | | official Homeopathic Pharmacopoeia
of the United
States, | 10 | | United States Dispensatory, or Remington's Practice of | 11 | | Pharmacy,
or any supplement to any of them; and (2)
articles | 12 | | intended for use in the diagnosis, cure, mitigation, treatment | 13 | | or
prevention of disease in man or other animals; and (3) | 14 | | articles (other than
food) intended to affect the structure or | 15 | | any function of the body of man
or other animals; and (4) | 16 | | articles intended for use as a component of any
article | 17 | | specified in clause (1), (2) or (3); but does not include | 18 | | devices
or their components, parts or accessories.
| 19 | | (b) "Synthetic drug product" means any product that | 20 | | contains a substance defined as a controlled substance under | 21 | | subsections (d) and (e) of Section 204 of the Illinois | 22 | | Controlled Substances Act. Products approved by the U.S. Food | 23 | | and Drug Administration for human consumption are not synthetic |
| | | HB5233 | - 2 - | LRB097 20167 RPM 65645 b |
|
| 1 | | drug products. | 2 | | (Source: P.A. 84-891.)
| 3 | | (410 ILCS 620/3.22) (from Ch. 56 1/2, par. 503.22)
| 4 | | Sec. 3.22.
(a) Whoever knowingly distributes, or possesses | 5 | | with intent to
distribute, human growth hormone for any use in | 6 | | humans other than the
treatment of a disease or other | 7 | | recognized medical condition, where the use
has been authorized | 8 | | by the Secretary of Health and Human Services and under
the | 9 | | order of a physician, is guilty of a Class 3 felony, and may be | 10 | | fined
an amount not to exceed $50,000. As used in this Section, | 11 | | the term "human growth hormone" means somatrem, somatropin, or | 12 | | an analogue of either of them.
| 13 | | (b) Whoever distributes, or possesses with intent to | 14 | | distribute, a synthetic drug product or a drug that is | 15 | | misbranded under this Act is guilty of a Class 2 felony and may | 16 | | be fined an amount not to exceed $100,000. A person convicted | 17 | | of a second or subsequent violation of this Section is guilty | 18 | | of a Class 1 felony, the fine for which shall not exceed | 19 | | $250,000. | 20 | | (c) Whoever falsely advertises a synthetic drug product or | 21 | | a drug that is misbranded is guilty of a Class 3 felony and may | 22 | | be fined an amount not to exceed $100,000. | 23 | | (d) Whoever commits any offense set forth in this Section | 24 | | and the offense
involves an individual under 18 years of age is | 25 | | punishable by not more than
10 years imprisonment, and twice |
| | | HB5233 | - 3 - | LRB097 20167 RPM 65645 b |
|
| 1 | | the fine authorized above. Any conviction
for a violation of | 2 | | this Section shall be considered a violation of the
Illinois | 3 | | Controlled Substances Act for the purposes of forfeiture under
| 4 | | Section 505 of such Act. As used in this Section the term | 5 | | "human growth
hormone" means somatrem, somatropin, or an | 6 | | analogue of either of them. The
Department of State Police and | 7 | | Department of Professional Regulation are
authorized to | 8 | | investigate offenses punishable by this Section.
| 9 | | (e) Any person convicted under this Section is subject to | 10 | | the forfeiture provisions set forth in subsections (c), (d), | 11 | | (e), (f), (g), (h), and (i) of Section 3.23 of this Act. | 12 | | (Source: P.A. 87-754.)
| 13 | | (410 ILCS 620/5) (from Ch. 56 1/2, par. 505)
| 14 | | Sec. 5.
(a) A person who violates any of the provisions of | 15 | | this Act,
other than Sections 3.22 and 6, is guilty of a Class | 16 | | C misdemeanor; but if
the violation is committed after a | 17 | | conviction of such person under this
Section has become final, | 18 | | the person shall be guilty of a Class A
misdemeanor. A person | 19 | | who violates the provisions of Section 6 of this Act
is guilty | 20 | | of a Class 3 felony A misdemeanor ; but if the violation is | 21 | | committed after
a conviction of such person under this Section | 22 | | has become final, the person
shall be guilty of a Class 2 4 | 23 | | felony.
| 24 | | (b) No person is subject to the penalties of subsection (a) | 25 | | of this
Section for (1) violating Section 3.1 or 3.3 if he |
| | | HB5233 | - 4 - | LRB097 20167 RPM 65645 b |
|
| 1 | | establishes a guaranty or
undertaking signed by and containing | 2 | | the name and address of the person
residing in the State of | 3 | | Illinois from whom he received the article in good
faith, to | 4 | | the effect that the article is not adulterated or misbranded
| 5 | | within the meaning of this Act, designating this Act; or (2) | 6 | | for having
violated clause (2) of Section 3.16 if such person | 7 | | acted in good faith and
had no reason to believe that the use | 8 | | of the punch, die, plate, stone or
other thing involved would | 9 | | result in a drug being a counterfeit drug, or
for having | 10 | | violated clause (3) of Section 3.16 if the person doing the act
| 11 | | or causing it to be done acted in good faith and had no reason | 12 | | to believe
that the drug was a counterfeit drug.
| 13 | | (c) No publisher, radio-broadcast licensee, agency or | 14 | | medium for the
dissemination of an advertisement, except the | 15 | | manufacturer, packer,
distributor or seller of the article to | 16 | | which a false advertisement relates
is liable under this | 17 | | Section for the dissemination of such false
advertisement | 18 | | unless he has refused on the request of the Director to
furnish | 19 | | the Director the name and post office address of the | 20 | | manufacturer,
packer, distributor, seller or advertising | 21 | | agency residing in the State of
Illinois who causes him to | 22 | | disseminate such advertisement.
| 23 | | (d) No person shall be subject to the penalties of | 24 | | subsection (a) of
this Section for a violation of Section 3 | 25 | | involving misbranded food if the
violation exists solely | 26 | | because the food is misbranded under subsection
(c) of Section |
| | | HB5233 | - 5 - | LRB097 20167 RPM 65645 b |
|
| 1 | | 11 because of its advertising, and no person shall be
subject | 2 | | to the penalties of subsection (a) of this Section for such a
| 3 | | violation unless the violation is committed with the intent to | 4 | | defraud
or mislead.
| 5 | | (Source: P.A. 86-704; 87-754.)
| 6 | | (410 ILCS 620/6) (from Ch. 56 1/2, par. 506)
| 7 | | Sec. 6.
(a) When an authorized agent of the Director finds | 8 | | or has probable
cause to believe that any food, drug, device or | 9 | | cosmetic is adulterated or
so misbranded as to be dangerous or | 10 | | fraudulent within the meaning of this
Act , or is in violation | 11 | | of Section 12, 17 or 17.1 of this Act, or is suspected to be a | 12 | | synthetic drug product, he or she
shall affix to such article a | 13 | | tag or other appropriate marking
giving notice that the article | 14 | | is or is suspected of being adulterated or
misbranded and has | 15 | | been detained or embargoed and warning all persons not
to | 16 | | remove or dispose of such article by sale or otherwise until | 17 | | permission
for removal or disposal is given by such agent or | 18 | | the court. It is unlawful
for any person to remove or dispose | 19 | | of such detained or embargoed article
by sale or otherwise | 20 | | without such permission.
| 21 | | (b) When an article detained or embargoed under subsection | 22 | | (a) of this
Section is found by such agent to be adulterated or | 23 | | misbranded or to be
in violation of Section 12, 17 or 17.1 of | 24 | | this Act or is suspected to be a synthetic drug product ,
he or | 25 | | she shall petition the
circuit court in whose jurisdiction the |
| | | HB5233 | - 6 - | LRB097 20167 RPM 65645 b |
|
| 1 | | article is detained or embargoed
for a libel for condemnation | 2 | | of such article. When such agent finds that an
article so | 3 | | detained or embargoed is not adulterated or misbranded or is | 4 | | not a synthetic drug product , he or
she shall remove the tag or | 5 | | other marking.
| 6 | | (c) If the court finds that a detained or embargoed article | 7 | | is
adulterated or misbranded, such article shall, after entry | 8 | | of the judgment, be
destroyed at the expense of the claimant | 9 | | thereof, under the supervision
of such agent, and all court | 10 | | costs and fees, and storage and other proper
expenses, shall be | 11 | | taxed against the claimant of such article or his or her
agent. | 12 | | However, when the adulteration or misbranding can be corrected | 13 | | by proper
labeling or processing of the article, the court, | 14 | | after entry of the judgment
and after such costs, fees and | 15 | | expenses have been paid and a good and
sufficient bond, | 16 | | conditioned that such article shall be so labeled or
processed, | 17 | | has been executed, may by order direct that such article be
| 18 | | delivered to the claimant thereof for such labeling or | 19 | | processing under the
supervision of an agent of the Director. | 20 | | The expense of such supervision
shall be paid by the claimant. | 21 | | The article shall be returned to the claimant
and the bond | 22 | | shall be discharged on the representation to the court by the
| 23 | | Director that the article is no longer in violation of this | 24 | | Act, and that
the expenses of such supervision have been paid.
| 25 | | (d) Whenever the Director or any of his or her authorized | 26 | | agents finds
in any room, building, vehicle of transportation |
| | | HB5233 | - 7 - | LRB097 20167 RPM 65645 b |
|
| 1 | | or other structure, any
meat, sea food, poultry, vegetable, | 2 | | fruit or other perishable articles
which contain any filthy, | 3 | | decomposed or putrid substance, or that may be
poisonous or | 4 | | deleterious to health or otherwise unsafe, the same being
| 5 | | hereby declared to be a nuisance, the Director or his or her | 6 | | authorized
agent shall condemn or destroy the same, or in any | 7 | | other manner render the
same unusable as human food.
| 8 | | (Source: P.A. 85-564.)
| 9 | | Section 10. The Illinois Controlled Substances Act is | 10 | | amended by changing Section 204 as follows: | 11 | | (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204) | 12 | | Sec. 204. (a) The controlled substances listed in this | 13 | | Section are
included in Schedule I. | 14 | | (b) Unless specifically excepted or unless listed in | 15 | | another
schedule, any of the following opiates, including their | 16 | | isomers,
esters, ethers, salts, and salts of isomers, esters, | 17 | | and ethers,
whenever the existence of such isomers, esters, | 18 | | ethers and salts is
possible within the specific chemical | 19 | | designation: | 20 | | (1) Acetylmethadol; | 21 | | (1.1) Acetyl-alpha-methylfentanyl | 22 | | (N-[1-(1-methyl-2-phenethyl)-
| 23 | | 4-piperidinyl]-N-phenylacetamide); | 24 | | (2) Allylprodine; |
| | | HB5233 | - 8 - | LRB097 20167 RPM 65645 b |
|
| 1 | | (3) Alphacetylmethadol, except
| 2 | | levo-alphacetylmethadol (also known as levo-alpha-
| 3 | | acetylmethadol, levomethadyl acetate, or LAAM); | 4 | | (4) Alphameprodine; | 5 | | (5) Alphamethadol; | 6 | | (6) Alpha-methylfentanyl
| 7 | | (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
| 8 | | propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
| 9 | | propanilido) piperidine; | 10 | | (6.1) Alpha-methylthiofentanyl
| 11 | | (N-[1-methyl-2-(2-thienyl)ethyl-
| 12 | | 4-piperidinyl]-N-phenylpropanamide); | 13 | | (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP); | 14 | | (7.1) PEPAP
| 15 | | (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine); | 16 | | (8) Benzethidine; | 17 | | (9) Betacetylmethadol; | 18 | | (9.1) Beta-hydroxyfentanyl
| 19 | | (N-[1-(2-hydroxy-2-phenethyl)-
| 20 | | 4-piperidinyl]-N-phenylpropanamide); | 21 | | (10) Betameprodine; | 22 | | (11) Betamethadol; | 23 | | (12) Betaprodine; | 24 | | (13) Clonitazene; | 25 | | (14) Dextromoramide; | 26 | | (15) Diampromide; |
| | | HB5233 | - 9 - | LRB097 20167 RPM 65645 b |
|
| 1 | | (16) Diethylthiambutene; | 2 | | (17) Difenoxin; | 3 | | (18) Dimenoxadol; | 4 | | (19) Dimepheptanol; | 5 | | (20) Dimethylthiambutene; | 6 | | (21) Dioxaphetylbutyrate; | 7 | | (22) Dipipanone; | 8 | | (23) Ethylmethylthiambutene; | 9 | | (24) Etonitazene; | 10 | | (25) Etoxeridine; | 11 | | (26) Furethidine; | 12 | | (27) Hydroxpethidine; | 13 | | (28) Ketobemidone; | 14 | | (29) Levomoramide; | 15 | | (30) Levophenacylmorphan; | 16 | | (31) 3-Methylfentanyl
| 17 | | (N-[3-methyl-1-(2-phenylethyl)-
| 18 | | 4-piperidyl]-N-phenylpropanamide); | 19 | | (31.1) 3-Methylthiofentanyl
| 20 | | (N-[(3-methyl-1-(2-thienyl)ethyl-
| 21 | | 4-piperidinyl]-N-phenylpropanamide); | 22 | | (32) Morpheridine; | 23 | | (33) Noracymethadol; | 24 | | (34) Norlevorphanol; | 25 | | (35) Normethadone; | 26 | | (36) Norpipanone; |
| | | HB5233 | - 10 - | LRB097 20167 RPM 65645 b |
|
| 1 | | (36.1) Para-fluorofentanyl
| 2 | | (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
| 3 | | 4-piperidinyl]propanamide); | 4 | | (37) Phenadoxone; | 5 | | (38) Phenampromide; | 6 | | (39) Phenomorphan; | 7 | | (40) Phenoperidine; | 8 | | (41) Piritramide; | 9 | | (42) Proheptazine; | 10 | | (43) Properidine; | 11 | | (44) Propiram; | 12 | | (45) Racemoramide; | 13 | | (45.1) Thiofentanyl
| 14 | | (N-phenyl-N-[1-(2-thienyl)ethyl-
| 15 | | 4-piperidinyl]-propanamide); | 16 | | (46) Tilidine; | 17 | | (47) Trimeperidine; | 18 | | (48) Beta-hydroxy-3-methylfentanyl (other name:
| 19 | | N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
| 20 | | N-phenylpropanamide). | 21 | | (c) Unless specifically excepted or unless listed in | 22 | | another
schedule, any of the following opium derivatives, its | 23 | | salts, isomers
and salts of isomers, whenever the existence of | 24 | | such salts, isomers and
salts of isomers is possible within the | 25 | | specific chemical designation: | 26 | | (1) Acetorphine; |
| | | HB5233 | - 11 - | LRB097 20167 RPM 65645 b |
|
| 1 | | (2) Acetyldihydrocodeine; | 2 | | (3) Benzylmorphine; | 3 | | (4) Codeine methylbromide; | 4 | | (5) Codeine-N-Oxide; | 5 | | (6) Cyprenorphine; | 6 | | (7) Desomorphine; | 7 | | (8) Diacetyldihydromorphine (Dihydroheroin); | 8 | | (9) Dihydromorphine; | 9 | | (10) Drotebanol; | 10 | | (11) Etorphine (except hydrochloride salt); | 11 | | (12) Heroin; | 12 | | (13) Hydromorphinol; | 13 | | (14) Methyldesorphine; | 14 | | (15) Methyldihydromorphine; | 15 | | (16) Morphine methylbromide; | 16 | | (17) Morphine methylsulfonate; | 17 | | (18) Morphine-N-Oxide; | 18 | | (19) Myrophine; | 19 | | (20) Nicocodeine; | 20 | | (21) Nicomorphine; | 21 | | (22) Normorphine; | 22 | | (23) Pholcodine; | 23 | | (24) Thebacon. | 24 | | (d) Unless specifically excepted or unless listed in | 25 | | another
schedule, any material, compound, mixture, or | 26 | | preparation which contains
any quantity of the following |
| | | HB5233 | - 12 - | LRB097 20167 RPM 65645 b |
|
| 1 | | hallucinogenic substances, or which
contains any of its salts, | 2 | | isomers and salts of isomers, whenever the
existence of such | 3 | | salts, isomers, and salts of isomers is possible
within the | 4 | | specific chemical designation (for the purposes of this
| 5 | | paragraph only, the term "isomer" includes the optical, | 6 | | position and
geometric isomers): | 7 | | (1) 3,4-methylenedioxyamphetamine
| 8 | | (alpha-methyl,3,4-methylenedioxyphenethylamine,
| 9 | | methylenedioxyamphetamine, MDA); | 10 | | (1.1) Alpha-ethyltryptamine
| 11 | | (some trade or other names: etryptamine;
| 12 | | MONASE; alpha-ethyl-1H-indole-3-ethanamine;
| 13 | | 3-(2-aminobutyl)indole; a-ET; and AET); | 14 | | (2) 3,4-methylenedioxymethamphetamine (MDMA); | 15 | | (2.1) 3,4-methylenedioxy-N-ethylamphetamine
| 16 | | (also known as: N-ethyl-alpha-methyl-
| 17 | | 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
| 18 | | and MDEA); | 19 | | (2.2) N-Benzylpiperazine (BZP); | 20 | | (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA); | 21 | | (4) 3,4,5-trimethoxyamphetamine (TMA); | 22 | | (5) (Blank); | 23 | | (6) Diethyltryptamine (DET); | 24 | | (7) Dimethyltryptamine (DMT); | 25 | | (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP); | 26 | | (9) Ibogaine (some trade and other names:
|
| | | HB5233 | - 13 - | LRB097 20167 RPM 65645 b |
|
| 1 | | 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
| 2 | | 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
| 3 | | indole; Tabernanthe iboga); | 4 | | (10) Lysergic acid diethylamide; | 5 | | (10.1) Salvinorin A; | 6 | | (10.5) Salvia divinorum (meaning all parts of the plant | 7 | | presently classified
botanically as Salvia divinorum, | 8 | | whether growing or not, the
seeds thereof, any extract from | 9 | | any part of that plant, and every compound,
manufacture, | 10 | | salts, isomers, and salts of
isomers whenever the existence | 11 | | of such salts, isomers, and salts of
isomers is possible | 12 | | within the specific chemical designation, derivative, | 13 | | mixture, or preparation of that plant, its
seeds or | 14 | | extracts);
| 15 | | (11) 3,4,5-trimethoxyphenethylamine (Mescaline); | 16 | | (12) Peyote (meaning all parts of the plant presently | 17 | | classified
botanically as Lophophora williamsii
Lemaire, | 18 | | whether growing or not, the
seeds thereof, any extract from | 19 | | any part of that plant, and every compound,
manufacture, | 20 | | salts, derivative, mixture, or preparation of that plant, | 21 | | its
seeds or extracts); | 22 | | (13) N-ethyl-3-piperidyl benzilate (JB 318); | 23 | | (14) N-methyl-3-piperidyl benzilate; | 24 | | (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
| 25 | | (also known as N-hydroxy-alpha-methyl-
| 26 | | 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA); |
| | | HB5233 | - 14 - | LRB097 20167 RPM 65645 b |
|
| 1 | | (15) Parahexyl; some trade or other names:
| 2 | | 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
| 3 | | dibenzo (b,d) pyran; Synhexyl; | 4 | | (16) Psilocybin; | 5 | | (17) Psilocyn; | 6 | | (18) Alpha-methyltryptamine (AMT); | 7 | | (19) 2,5-dimethoxyamphetamine
| 8 | | (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); | 9 | | (20) 4-bromo-2,5-dimethoxyamphetamine
| 10 | | (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
| 11 | | 4-bromo-2,5-DMA); | 12 | | (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
| 13 | | Some trade or other names: 2-(4-bromo-
| 14 | | 2,5-dimethoxyphenyl)-1-aminoethane;
| 15 | | alpha-desmethyl DOB, 2CB, Nexus; | 16 | | (21) 4-methoxyamphetamine
| 17 | | (4-methoxy-alpha-methylphenethylamine;
| 18 | | paramethoxyamphetamine; PMA); | 19 | | (22) (Blank); | 20 | | (23) Ethylamine analog of phencyclidine.
| 21 | | Some trade or other names:
| 22 | | N-ethyl-1-phenylcyclohexylamine,
| 23 | | (1-phenylcyclohexyl) ethylamine,
| 24 | | N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE; | 25 | | (24) Pyrrolidine analog of phencyclidine. Some trade | 26 | | or other names:
1-(1-phenylcyclohexyl) pyrrolidine, PCPy, |
| | | HB5233 | - 15 - | LRB097 20167 RPM 65645 b |
|
| 1 | | PHP; | 2 | | (25) 5-methoxy-3,4-methylenedioxy-amphetamine; | 3 | | (26) 2,5-dimethoxy-4-ethylamphetamine
| 4 | | (another name: DOET); | 5 | | (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
| 6 | | (another name: TCPy); | 7 | | (28) (Blank); | 8 | | (29) Thiophene analog of phencyclidine (some trade
| 9 | | or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
| 10 | | 2-thienyl analog of phencyclidine; TPCP; TCP); | 11 | | (30) Bufotenine (some trade or other names:
| 12 | | 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
| 13 | | 3-(2-dimethylaminoethyl)-5-indolol;
| 14 | | 5-hydroxy-N,N-dimethyltryptamine;
| 15 | | N,N-dimethylserotonin; mappine); | 16 | | (31) 1-Pentyl-3-(1-naphthoyl)indole | 17 | | Some trade or other names: JWH-018; | 18 | | (32) 1-Butyl-3-(1-naphthoyl)indole | 19 | | Some trade or other names: JWH-073; | 20 | | (33) 1-[(5-fluoropentyl)-1H-indol-3-yl]- | 21 | | (2-iodophenyl)methanone | 22 | | Some trade or other names: AM-694; | 23 | | (34) 2-[ ( 1R,3S)-3-hydroxycyclohexyl]-5- | 24 | | (2-methyloctan-2-yl)phenol | 25 | | Some trade or other names: CP 47,497 47, 497 | 26 | | and its C6, C8 and C9 homologs; |
| | | HB5233 | - 16 - | LRB097 20167 RPM 65645 b |
|
| 1 | | (34.5) (33) 2-[(1R,3S)-3-hydroxycyclohexyl]-5- | 2 | | (2-methyloctan-2-yl)phenol), where side chain n=5; | 3 | | and homologues where side chain n=4, 6, or 7; Some | 4 | | trade or other names: CP 47,497; | 5 | | (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- | 6 | | (2-methyloctan-2-yl)-6a,7, | 7 | | 10,10a-tetrahydrobenzo[c]chromen-1-ol | 8 | | Some trade or other names: HU-210; | 9 | | (35.5) (34) (6aS,10aS)-9-(hydroxymethyl)-6,6- | 10 | | dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- | 11 | | tetrahydrobenzo[c]chromen-1-ol, its isomers, | 12 | | salts, and salts of isomers; Some trade or other | 13 | | names: HU-210, Dexanabinol; | 14 | | (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)- | 15 | | 6,6-dimethyl-3-(2-methyloctan-2-yl)- | 16 | | 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol | 17 | | Some trade or other names: HU-211; | 18 | | (37) (2-methyl-1-propyl-1H-indol- | 19 | | 3-yl)-1-naphthalenyl-methanone | 20 | | Some trade or other names: JWH-015; | 21 | | (38) 4-methoxynaphthalen-1-yl- | 22 | | (1-pentylindol-3-yl)methanone | 23 | | Some trade or other names: JWH-081; | 24 | | (39) ( 1-Pentyl-3-(4-methyl-1-naphthoyl)indole | 25 | | Some trade or other names: JWH-122; | 26 | | (40) 2-(2-methylphenyl)-1-(1-pentyl- |
| | | HB5233 | - 17 - | LRB097 20167 RPM 65645 b |
|
| 1 | | 1H-indol-3-yl)-ethanone | 2 | | Some trade or other names: JWH-251; | 3 | | (41) 1-(2-cyclohexylethyl)-3- | 4 | | (2-methoxyphenylacetyl)indole | 5 | | Some trade or other names: RCS-8, BTW-8 and SR-18 ; . | 6 | | (42) (33) Any compound structurally derived from | 7 | | 3-(1-naphthoyl)indole or 1H-indol-3-yl- | 8 | | (1-naphthyl)methane by substitution at the | 9 | | nitrogen atom of the indole ring by alkyl, haloalkyl, | 10 | | alkenyl, cycloalkylmethyl, cycloalkylethyl or | 11 | | 2-(4-morpholinyl)ethyl whether or not further | 12 | | substituted in the indole ring to any extent, whether | 13 | | or not substituted in the naphthyl ring to any extent; | 14 | | (43) (34) Any compound structurally derived from | 15 | | 3-(1-naphthoyl)pyrrole by substitution at the nitrogen | 16 | | atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, | 17 | | cycloalkylmethyl, cycloalkylethyl or | 18 | | 2-(4-morpholinyl)ethyl, whether or not further | 19 | | substituted in the pyrrole ring to any extent, whether | 20 | | or not substituted in the naphthyl ring to any extent; | 21 | | (44) (35) Any compound structurally derived from | 22 | | 1-(1-naphthylmethyl)indene by substitution | 23 | | at the 3-position of the indene ring by alkyl, haloalkyl, | 24 | | alkenyl, cycloalkylmethyl, cycloalkylethyl or | 25 | | 2-(4-morpholinyl)ethyl whether or not further | 26 | | substituted in the indene ring to any extent, whether |
| | | HB5233 | - 18 - | LRB097 20167 RPM 65645 b |
|
| 1 | | or not substituted in the naphthyl ring to any extent; | 2 | | (45) (36) Any compound structurally derived from | 3 | | 3-phenylacetylindole by substitution at the | 4 | | nitrogen atom of the indole ring with alkyl, haloalkyl, | 5 | | alkenyl, cycloalkylmethyl, cycloalkylethyl or | 6 | | 2-(4-morpholinyl)ethyl, whether or not further | 7 | | substituted in the indole ring to any extent, whether | 8 | | or not substituted in the phenyl ring to any extent; | 9 | | (46) (37) Any compound structurally derived from | 10 | | 2-(3-hydroxycyclohexyl)phenol by substitution | 11 | | at the 5-position of the phenolic ring by alkyl, | 12 | | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl | 13 | | or 2-(4-morpholinyl)ethyl, whether or not substituted | 14 | | in the cyclohexyl ring to any extent ; . | 15 | | (47) (33) 3,4-Methylenedioxymethcathinone | 16 | | Some trade or other names: Methylone; | 17 | | (48) (34) 3,4-Methyenedioxypyrovalerone | 18 | | Some trade or other names: MDPV; | 19 | | (49) (35) 4-Methylmethcathinone | 20 | | Some trade or other names: Mephedrone; | 21 | | (50) (36) 4-methoxymethcathinone; | 22 | | (51) (37) 4-Fluoromethcathinone; | 23 | | (52) (38) 3-Fluoromethcathinone ; . | 24 | | (53) (35) 2,5-Dimethoxy-4-(n)-propylthio- | 25 | | phenethylamine; | 26 | | (54) (36) 5-Methoxy-N,N-diisopropyltryptamine ; . |
| | | HB5233 | - 19 - | LRB097 20167 RPM 65645 b |
|
| 1 | | (55) Pentedrone. | 2 | | (e) Unless specifically excepted or unless listed in | 3 | | another
schedule, any material, compound, mixture, or | 4 | | preparation which contains
any quantity of the following | 5 | | substances having a depressant effect on
the central nervous | 6 | | system, including its salts, isomers, and salts of
isomers | 7 | | whenever the existence of such salts, isomers, and salts of
| 8 | | isomers is possible within the specific chemical designation: | 9 | | (1) mecloqualone; | 10 | | (2) methaqualone; and | 11 | | (3) gamma hydroxybutyric acid. | 12 | | (f) Unless specifically excepted or unless listed in | 13 | | another schedule,
any material, compound, mixture, or | 14 | | preparation which contains any quantity
of the following | 15 | | substances having a stimulant effect on the central nervous
| 16 | | system, including its salts, isomers, and salts of isomers: | 17 | | (1) Fenethylline; | 18 | | (2) N-ethylamphetamine; | 19 | | (3) Aminorex (some other names:
| 20 | | 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
| 21 | | 4-5-dihydro-5-phenyl-2-oxazolamine) and its
| 22 | | salts, optical isomers, and salts of optical isomers; | 23 | | (4) Methcathinone (some other names:
| 24 | | 2-methylamino-1-phenylpropan-1-one;
| 25 | | Ephedrone; 2-(methylamino)-propiophenone;
| 26 | | alpha-(methylamino)propiophenone; N-methylcathinone;
|
| | | HB5233 | - 20 - | LRB097 20167 RPM 65645 b |
|
| 1 | | methycathinone; Monomethylpropion; UR 1431) and its
| 2 | | salts, optical isomers, and salts of optical isomers; | 3 | | (5) Cathinone (some trade or other names:
| 4 | | 2-aminopropiophenone; alpha-aminopropiophenone;
| 5 | | 2-amino-1-phenyl-propanone; norephedrone); | 6 | | (6) N,N-dimethylamphetamine (also known as:
| 7 | | N,N-alpha-trimethyl-benzeneethanamine;
| 8 | | N,N-alpha-trimethylphenethylamine); | 9 | | (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
| 10 | | 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine); | 11 | | (8) 3,4-Methylenedioxypyrovalerone (MDPV). | 12 | | (g) Temporary listing of substances subject to emergency | 13 | | scheduling.
Any material, compound, mixture, or preparation | 14 | | that contains any quantity
of the following substances: | 15 | | (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
| 16 | | (benzylfentanyl), its optical isomers, isomers, salts,
| 17 | | and salts of isomers; | 18 | | (2) N-[1(2-thienyl)
| 19 | | methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl),
| 20 | | its optical isomers, salts, and salts of isomers. | 21 | | (Source: P.A. 96-347, eff. 1-1-10; 96-1285, eff. 1-1-11; | 22 | | 97-192, eff. 7-22-11; 97-193, eff. 1-1-12; 97-194, eff. | 23 | | 7-22-11; 97-334, eff. 1-1-12; revised 9-14-11.)
|
|